Valuation: CareDx, Inc.

Capitalization 1.15B 975M 900M 849M 1.57B 107B 1.6B 10.55B 4.14B 51.4B 4.31B 4.22B 183B P/E ratio 2026 *
-1,281x
P/E ratio 2027 * 65.5x
Enterprise value 1.15B 975M 900M 849M 1.57B 107B 1.6B 10.55B 4.14B 51.4B 4.31B 4.22B 183B EV / Sales 2026 *
2.63x
EV / Sales 2027 * 2.39x
Free-Float
96.56%
Yield 2026 *
-
Yield 2027 * -
1 day+27.60%
1 week+34.33%
Current month+29.15%
1 month+29.45%
3 months+12.04%
6 months+49.57%
Current year+19.00%
1 week 15.8
Extreme 15.8047
22.81
1 month 15.56
Extreme 15.56
22.81
Current year 15.56
Extreme 15.56
22.81
1 year 10.96
Extreme 10.96
22.81
3 years 4.8
Extreme 4.8
34.84
5 years 4.8
Extreme 4.8
96.88
10 years 0.76
Extreme 0.76
99.83
Manager TitleAgeSince
Chief Executive Officer 46 2024-04-14
Director of Finance/CFO 56 2026-02-25
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 68 2021-10-31
Chairman 59 2019-12-31
Director/Board Member 70 2014-04-07
Change 5d. change 1-year change 3-years change Capi.($)
+27.60%+34.33%+23.05%+152.48% 1.15B
-2.97%+5.36%+4.76%+50.62% 2.62B
+0.32%+1.38%-16.28%-46.42% 2.27B
-3.10%+5.07%+87.98%+78.00% 2.17B
-0.52%-5.24%+23.78%-32.62% 1.57B
-2.68%+17.95%+296.07% - 1.05B
+2.26%+6.64%+2.68%-7.43% 776M
+0.59%-0.29%-7.32%-10.38% 703M
-2.57%+9.65%+98.26%-75.83% 499M
+0.79%+15.19% - - 471M
Average +1.97%+8.45%+57.00%+13.55% 1.33B
Weighted average by Cap. +1.17%+6.94%+45.82%+22.94%

Financials

2026 *2027 *
Net sales 437M 371M 343M 323M 599M 40.65B 609M 4.01B 1.57B 19.56B 1.64B 1.6B 69.54B 481M 409M 377M 356M 660M 44.76B 671M 4.42B 1.73B 21.54B 1.8B 1.77B 76.57B
Net income -684K -581K -536K -506K -938K -63.64M -954K -6.29M -2.46M -30.62M -2.57M -2.51M -109M 18.14M 15.4M 14.22M 13.41M 24.87M 1.69B 25.3M 167M 65.33M 812M 68.04M 66.62M 2.89B
Net Debt - -
Logo CareDx, Inc.
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Company’s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
Employees
763
Date Price Change Volume
26-04-16 22.42 $ +27.60% 2,964,543
26-04-15 17.57 $ -0.34% 594,225
26-04-14 17.63 $ +4.75% 606,910
26-04-13 16.83 $ +4.86% 504,527
26-04-10 16.05 $ -3.83% 784,273
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
22.42USD
Average target price
24.80USD
Spread / Average Target
+10.62%

Quarterly revenue - Rate of surprise